Triple negative breast carcinomas (TNBCs) are a group of primary breast tumorswith aggressive clinical behavior that have no targeted therapy at present. EGFRexpression has recently come into focus as an index for molecular targetingtherapy. Histologic sections that included variable subtypes and grades ofTNBCs were studied by immunohistochemistry with EGFR, using a standardavidin–biotin–peroxidase system.